|
3rd of August 2010 Meta-IQ is selected to present on the 7th of September at the semi finals of European Venture Contest (EEVC) 2010 in Aarhus, Denmark.
3rd of August 2010 Metabolistik Consulting is selected to present on the 7th of September at the semi finals of European Venture Contest (EEVC) 2010 in Aarhus, Denmark.
1st of April 2010 Meta-IQ has moved to new inspiring office building at Augustenborggade 2, 1s, 8000 Aarhus C. Denmark.
27th of January 2010 Meta-IQ has presented its systemic thinking approach in the treatment of brain diseases at the Center for Psychiatric Research, Aarhus University Hospital Risskov Denmark. See presentation
2nd of January 2010 Meta-IQ Dr. Peter Heinrich has joined the Meta-IQ management team as Key Advisor Bibliography of Dr Peter Heinrich.
17th of August 2009 Meta-IQ has the first data showing a highly significant efficacy of MIQ-003 in the treatment of Multiple Sclerosis in a therapeutic animal model.
13th of July 2009 Meta-IQ Article in the Jylandsposten newspaper on Meta-IQ collabration with international and national research institutes and Universities. Read article here.
6th of July 2009 Meta-IQ has started the final proof of concept testing of M-IQ 003 in different Multiple sclerosis animal models
24th of June 2009 Meta-IQ presented at the Business Development Conference 2009 in Munich, Germany. See picture
5th of May 2009 Metabolistik: The US patent office decided to grant new US patent on fatty acid oxidation blockers in skin diseases.
23rd of April 2009 Meta-IQ is an invited speaker at the Anglonordic Biotech Conference in London. Meta-IQ will present in the Atlas Venture Investment Room
From 30th of March till 10th of April 2009 Meta-IQ is meeting with Venture capital companies in California.
29th of March 2009 Meta-IQ appoints Jette Nieland as the CEO and John Nieland as the COO of the company
4th of September 2008 Meta-IQ is at a private conference presented to the public
June 2008 Meta-IQ files a patent for brain disease treatment
May 2008 Meta-IQ generated excellent preclinical data showing efficacy of its drug M-IQ 002 in Depression
April 2008 Meta-IQ generated excellent preclinical data showing efficacy of its drug M-IQ 001 in restoration of short and long term memory in an Alzheimer memory loss model
|
Management
